<DOC>
	<DOCNO>NCT02591082</DOCNO>
	<brief_summary>This observational study assess patient survival clinical outcome RenovoCath™ RC120 catheter use deliver chemotherapeutic agent pancreatic tumor .</brief_summary>
	<brief_title>Intra-Arterial Treatment Pancreatic Cancer Using RenovoCath™ RC120 Catheter</brief_title>
	<detailed_description>This observational , registry study assess patient survival clinical outcome RenovoCath™ RC120 catheter use deliver chemotherapeutic agent pancreatic tumor . Blood sample draw subset patient assess systemic concentration chemotherapeutic agent . The RenovoCath™ RC120 Catheter endovascular multi-lumen , two-handled catheter design isolate variable segment artery supply target organ use two slideable , compliant balloon . Upon inflation proximal occlusion balloon distal occlusion balloon , catheter may isolate select site specifically deliver radiopaque therapeutic agent include , limited chemotherapeutic drug .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>18 year age Diagnosed unresectable borderline resectable pancreatic adenocarcinoma confirm histology cytology Without current myelotoxicity sufficient health status undergo catheterization procedure Willing provide inform consent comply require followup . Have receive prior chemotherapy and/or radiation therapy within 14 day prior first intraarterial treatment . Currently participate another active drug device study registry protocol would interfere study . Vulnerable population : prisoner , pregnant breastfeeding female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>